Cargando…

CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban

INTRODUCTION: The aim of this study is to assess the influence of gene CYP2C19, CYP3A4, CYP3A5 and ABCB1 polymorphisms on clopidogrel antiplatelet activity, rivaroxaban concentration equilibrium, and clinical outcomes among patients with acute coronary syndrome and non-valvular atrial fibrillation....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sychev, DA, Baturina, OA, Mirzaev, KB, Rytkin, E, Ivashchenko, DV, Andreev, DA, Ryzhikova, KA, Grishina, EA, Bochkov, PO, Shevchenko, RV
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986167/ https://www.ncbi.nlm.nih.gov/pubmed/32158254 http://dx.doi.org/10.2147/PGPM.S234910

Ejemplares similares

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?
por: Rytkin, Eric, et al.
Publicado: (2017)

Editorial: The utilization of bench-to-bedside approaches in pharmacogenomics
por: Rytkin, Eric, et al.
Publicado: (2023)

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations
por: Sychev, Dmitrij Alekseevitch, et al.
Publicado: (2017)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
por: Denisenko, Natalia P, et al.
Publicado: (2018)

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke
por: Kryukov, Alexander Valerevich, et al.
Publicado: (2018)

MicroRNAs as Novel Biomarkers for P2Y12 – Inhibitors Resistance Prediction
por: Rytkin, Eric, et al.
Publicado: (2021)

Pharmacogenetic markers to predict safety of antipsychotics in adolescents experiencing acute psychotic episodes
por: Ivashchenko, D., et al.
Publicado: (2022)

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction
por: Zastrozhin, Mikhail Sergeevich, et al.
Publicado: (2017)

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty
por: Sychev, Dmitriy Alekseevich, et al.
Publicado: (2018)

Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients
por: Denisenko, Natalia P, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy
por: Baturina, Olga, et al.
Publicado: (2023)

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
por: Mirzaev, Karin B, et al.
Publicado: (2017)

Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension
por: Sychev, Dmitry, et al.
Publicado: (2018)

Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder
por: Zastrozhin, Mikhail Sergeevich, et al.
Publicado: (2017)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
por: Sychev, DA, et al.
Publicado: (2015)

Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients
por: Bai, Long, et al.
Publicado: (2022)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet‐dependent thrombin generation in cats
por: Lo, Sara T., et al.
Publicado: (2023)

The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation
por: Wu, Tingting, et al.
Publicado: (2023)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
por: Kubitza, Dagmar, et al.
Publicado: (2012)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction
por: Sychev, Dmitry Alekseevich, et al.
Publicado: (2016)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Effect of Evidence-Based Pharmacy Care on Satisfaction and Cognition in Patients with Non-Valvular Atrial Fibrillation Taking Rivaroxaban
por: Sun, Jie, et al.
Publicado: (2021)

Increased Levels of Platelets and Endothelial-Derived Microparticles in Patients With Non-Valvular Atrial Fibrillation During Rivaroxaban Therapy
por: Lenart-Migdalska, Aleksandra, et al.
Publicado: (2021)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
por: Singkham, Noppaket, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

Non-Traumatic Spontaneous Spinal Subdural Hematoma in a Patient with Non-Valvular Atrial Fibrillation During Treatment with Rivaroxaban
por: Castillo, Jessica M., et al.
Publicado: (2015)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vs7upgpei2vjtlrlf9l4op75ut